COMMUNIQUÉS West-GlobeNewswire

Coloplast A/S - Coloplast presents new 5-year strategy, Impact4
02/09/2025
The new 5-year strategy, Impact4 , will be presented today at the company’s Capital Markets Day 2025 The Impact4 strategy puts customers at the centre of everything we do and sets an ambitious goal for the company – to [...]
Novaremed Announces Completion of All Patient Visits in NIH-Funded Phase 2b Trial of Non-Opioid Nispomeben for Treating Chronic Pain Associated with Diabetic Peripheral Neuropathy
02/09/2025
Last patient last visit (LPLV) was reached for the 127 adult and elderly patients enrolled into the 12-week placebo-controlled trial with nispomeben (NRD.E1) Topline results are expected in November 2025 The trial [...]
OMass Therapeutics Enters into Exclusive Collaboration and License Agreement with Genentech to Develop and Commercialize Therapies for Inflammatory Bowel Disease
02/09/2025
Collaboration leverages OMass’ Odyssion TM platform for the continued development of oral small molecules against a first-in-class target in inflammatory bowel disease OMass to receive $20 million upfront payment, with [...]
Hemex expands Global Clinical Network Alliance to strengthen end-to-end CRO Capabilities
02/09/2025
A newly established global alliance integrating specialized expertise in oncology, medical imaging, patient recruitment as well as pharmacokinetics and pharmacodynamics studies Comprehensive access to international [...]
Pharming Group appoints Kenneth Lynard as Chief Financial Officer
02/09/2025
Leiden, the Netherlands, September 2, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced the appointment of Kenneth Lynard as Chief Financial Officer (CFO), effective [...]
ONWARD Medical Demonstrates Commercial Traction and Advances Pipeline in the First Half of 2025
02/09/2025
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) EINDHOVEN, The Netherlands, Sept. 02, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. ( [...]
Coloplast A/S - Announcement no. 07/2025 - Coloplast announces new financial ambition towards 2030
02/09/2025
In relation to the launch of Coloplast’s new 5-year strategy, Impact4, the company announces a new financial ambition with organic revenue CAGR of 7-8% until FY 2029/30, growth in absolute EBIT* in line with or above [...]
CHARM Therapeutics raises $80 million in Series B financing to advance development of best-in-class menin inhibitor for AML
02/09/2025
New investors NEA and SR One lead round alongside existing investors OrbiMed, F-Prime, NVIDIA and Khosla Ventures CHARM’s AI-designed menin inhibitor overcomes resistance mutations with the potential to deliver superior [...]
FIRST PATIENT DOSED IN CITRYLL’S PHASE IIA TRIAL EVALUATING CIT-013 IN RHEUMATOID ARTHRITIS
02/09/2025
Randomized multi-center study designed to assess the efficacy, safety, and tolerability of CIT-013 in patients with moderately active rheumatoid arthritis Oss, Netherlands – 2 September 2025 – Citryll, a biotech company [...]
Upstream Bio to Host Conference Call and Webcast to Report Top-Line Data from the Phase 2 VIBRANT Trial of Verekitug in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
01/09/2025
– Conference Call and Webcast to be held Tuesday, September 2, 2025, at 8:00 a.m. ET – WALTHAM, Mass., Sept. 01, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments [...]
Healthcare Champions Launch Public Education Campaign to Address New Mexico’s Medical Access Crisis
01/09/2025
Santa Fe, NM, Sept. 01, 2025 (GLOBE NEWSWIRE) -- A new public education campaign has been launched by Patient-Led NM, founded by the New Mexico Medical Society, New Mexico Hospital Association, Sacramento Mountains [...]
Idorsia furthers the science of sleep and insomnia at World Sleep 2025
01/09/2025
Allschwil, Switzerland – September 1, 2025 Idorsia Ltd (SIX: IDIA) continues its commitment to furthering the science of sleep and insomnia with a symposium and eight poster presentations at World Sleep 2025, a global [...]
EssilorLuxottica: Nombre total de droits de vote et d’actions composant le capital social au 31 juillet 2025
01/09/2025
Nombre total de droits de vote et d’actions composant le capital social au 31 juillet 2025 (Conformément à l’article L.233-8 II du Code de Commerce et aux articles 221-1 et 223-16 du Règlement Général de l’AMF) Paris, [...]
EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as of July 31, 2025
01/09/2025
Disclosure of Share Capital and Voting Rights Outstanding as of July 31, 2025 (Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des [...]
Grant of Warrants
01/09/2025
September 1, 2025 Announcement no. 20 Grant of Warrants Copenhagen, Denmark, September 1, 2025, (GLOBE NEWSWIRE) – The Board of Directors of BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR) has today decided to [...]
KFSHRC to Participate as Strategic Partner in C3 Davos of Healthcare New York Summit
01/09/2025
NEW YORK, Sept. 01, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) is participating as a Strategic Partner in the C3 Davos of Healthcare New York Summit, “Healthcare Disrupted: [...]
Communiqué de presse : Yves Jacob nommé responsable R&D France de Sanofi à compter du 1er septembre
01/09/2025
Yves Jacob nommé responsable R&D France de Sanofi à compter du 1 er septembre Gentilly (France), le 1 er septembre 2025 – Sanofi annonce la nomination d’ Yves Jacob en tant que Responsable R&D France . Yves [...]
Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences
01/09/2025
ZUG, Switzerland, Sept. 01, 2025 (GLOBE NEWSWIRE) -- Phase 2 ACUITY trial results for Privosegtor (OCS-05) in acute optic neuritis to be presented in EURETINA late-breaking session Expanded data analysis from Phase 3 [...]
Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences
01/09/2025
Phase 2 ACUITY trial results for Privosegtor (OCS-05) in acute optic neuritis to be presented in EURETINA late-breaking session Expanded data analysis from Phase 3 Stage 1 DIAMOND program for OCS-01 eye drops in [...]

Pages